Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

Inclusion Criteria: * Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastases * Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 * Anticipated life expectancy ≥ 12 weeks * Radiographically measurable disease acc. to RECIST 1.1 * Use of adequate contraception (as described in protocol) * Ability to provide written informed consent and comply with study requirements Exclusion Criteria: * Received other cancer treatment or investigational drug within 4 weeks prior to screening * Women who are pregnant or breastfeeding * Had major surgery within 4 weeks of first dose of study drug * Inadequate liver, renal or bone marrow function within 2 weeks of first dose * Serious concurrent illness, altered medical status or any uncontrolled medical condition * Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening * Known active HIV, HBV or HCV infection * Inability to swallow tablets * History or presence of any medical condition or disease which, in the opinion of the investigator, may place the subject at unacceptable risk for study participation